NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE Drug Patent Profile

Which patents cover Norepinephrine Bitartrate In 0.9% Sodium Chloride, and what generic alternatives are available?

Norepinephrine Bitartrate In 0.9% Sodium Chloride is a drug marketed by Baxter Hlthcare Corp, Inforlife, and Long Grove Pharms. and is included in three NDAs. There are ten patents protecting this drug.

This drug has forty-nine patent family members in forty countries.

The generic ingredient in NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE is norepinephrine bitartrate. There are five drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norepinephrine Bitartrate In 0.9% Sodium Chloride

A generic version of NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE was approved as norepinephrine bitartrate by MEITHEAL on March 3^rd, 2003.

Summary for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

International Patents:	49
US Patents:	10
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	3
Clinical Trials:	12
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
DailyMed Link:	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE at DailyMed

Recent Clinical Trials for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Siriraj Hospital	PHASE1
Visarat Palitnonkiat	PHASE1
Hassan II University	PHASE4

See all NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE clinical trials

Pharmacology for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

Drug Class

Catecholamine

US Patents and Regulatory Information for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE is protected by ten US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-003	Oct 6, 2022		RX	Yes	Yes	10,568,850		Y
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-003	Oct 6, 2022		RX	Yes	Yes	11,413,259		Y
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-003	Oct 6, 2022		RX	Yes	Yes	12,245,996		Y
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-003	Oct 6, 2022		RX	Yes	Yes	10,420,735		Y
Baxter Hlthcare Corp	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214313-004	Feb 6, 2026		RX	Yes	Yes

International Patents for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

See the table below for patents covering NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	I673065
Peru	20161375	PROCESO PARA PRODUCIR UNA SOLUCION INYECTABLE DE NORADRENALINA DE BAJA CONCENTRACION, ESTABLE
Jordan	3552	عملية لإنتاج محلول نورادرينالين ذو تركيز منخفض مستقر قابل للحقن (Process for producing a stable low concentration, injectable solution of noradrenaline)
Mexico	367148	PROCESO PARA PRODUCIR UNA SOLUCIÓN INYECTABLE DE NORADRENALINA DE BAJA CONCENTRACIÓN, ESTABLE. (PROCESS FOR PRODUCING A STABLE LOW CONCENTRATION, INJECTABLE SOLUTION OF NORADRENALINE.)
World Intellectual Property Organization (WIPO)	2021178946